The Cochrane Renal Group

This booklet contains information about: -

- **How we can help you**
- **The Review process**
- **List of Cochrane Renal Group reviews, protocols and titles**
- **Upcoming workshops and meetings**
- **Title registration form**

We look forward to working with you.

Cochrane Renal Group Editorial Team

Endorsements: Asia Pacific Society of Nephrology, International Pediatric Nephrology Association, International Society of Nephrology, National Kidney Foundation

Introduction

Thank you for becoming a member of the Cochrane Renal Group. As a new member you will receive a Cochrane Renal Group pen (as a way to say thanks), regular newsletters, notices about upcoming meetings and issues relevant to our group. There is no obligation as a member to anything, however, you can contribute in several ways.

- **Conducting a systematic review**
- **As a referee of systematic reviews**
- **Notifying the editorial base of any randomised controlled trials in kidney disease currently being undertaken or not published**
- **Carrying out hand-searching of journals particularly those that are not listed in Medline, and those published in languages other than English**
- **Sending abstract books of conference proceedings to the Editorial Base**
- **Offering technical or other support to members of the group**
- **Providing Consumer input**

Of these, the most important task is the development of systematic reviews, and in the following sections we have provided some guidance. If you have any queries at all please contact the Editorial base.

How we can help you

The Renal Group's aim is to make the review process as painless as possible. For example you will have access to and help with:

- **Access to the Renal Group's register of trials and we will provide a list of relevant trials**
- **Support with developing additional electronic and handsearching strategies**
- **Data collection checklists, which describes the inclusion criteria for studies, quality issues, and the collection of relevant data.**
- **Provide free workshops for all our authors**
- **Handbooks and software**
- **Phone and email support**
- **If required we will provide 1-2 weeks at the Editorial Base to help develop and complete reviews and protocols**

The Review Process

The Cochrane Collaboration is an organisation committed to improving health care practice through the production of systematic reviews. If you think that you may be interested in undertaking a review for the Cochrane Renal Group, the first thing to do is to approach the Editorial Base in Sydney.

Enquiries about the Cochrane Renal Group's review process are most welcome and will not be viewed as a commitment to undertake a review.



A Cochrane review is submitted in four stages:

1. **The title**
2. **The protocol**
3. **The review**
4. **Updating**

From idea to title

Once you think you would like to undertake a Cochrane Renal Group review, please notify the Editorial Base of a topic area you are interested in. They will assist you in formulating your idea into a title that fits within the scope of the group and doesn't overlap with any existing titles. You will then be asked to complete a 'Title Registration Form'. The Cochrane Collaboration has a set format for titles so please refer to page 6 of this

booklet. When your title has been approved by the editorial office, you will be assigned a unique identifier. Your registered title is then circulated to all other Review Groups to ensure there is no crossover. If you discover that your idea for a review is already being addressed, you may be able to collaborate with them or develop an alternate idea.

An information booklet on writing a protocol will be forwarded to you on registration of your title. New booklets shall be forwarded at each stage of the review process.

After title registration

It is important that you read Chapter 2 of the Cochrane Handbook for Systematic Reviews of Interventions: Format of a Cochrane Review.
Chapter 2 indicates the methods and layout of a Cochrane review: reviews must conform to the specifications outlined in this section. This section will be forwarded to you on registration of your title. However reading it beforehand is of great benefit (you can read and/or download from www.cochrane-handbook.org).

The Cochrane Renal Group's aim is that all reviews undertaken for the group will be published in the Cochrane Database of Systematic Reviews (CDSR) within *The Cochrane Library*. *The Cochrane Library* is the main 'product' of The Cochrane Collaboration: it contains all the Cochrane reviews and protocols produced by the different Review Groups, in addition to a number of important, related databases.

Developing a protocol

Protocols expand on the title to describe the review.

As a rough guide, your protocol will need to address the following issues:

1. **The specific purpose (question to be answered) of the review**
2. **The comparison groups (as the stated comparisons are central to each review, particular care should be taken with their development)**
3. **The sources and search methods used to find evidence (primary studies)**
4. **Explicit criteria for deciding which studies to include in the review**
5. **Avoidance of bias in the selection of articles**
6. **Reasons for excluding studies from the review**
7. **Appropriate criteria for assessing the quality of the studies**
8. **Appropriate methods (whether qualitative or quantitative) for combining the findings**

When you have developed your protocol to your own satisfaction, it should be submitted to the Editorial Base. This means it will be entered into the Renal Group's referee process, en route to inclusion in *The Cochrane Library*.

Submission of the protocol is taken as your agreement to undertake a Renal Group systematic review. Therefore, you should only submit the protocol if this is your intention.

Headings of a Cochrane protocol

(Extract from Chapter 2 of the *Cochrane Handbook for Systematic Reviews of Interventions*)

Text:

- **BACKGROUND**
- **OBJECTIVES**
- **CRITERIA FOR SELECTING STUDIES FOR THIS REVIEW**
  - **TYPES OF STUDIES**
  - **TYPES OF PARTICIPANTS**
  - **TYPES OF INTERVENTION(S)**
  - **TYPES OF OUTCOME MEASURES**
- **SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES**
- **DATA COLLECTION AND ANALYSIS**
- **ACKNOWLEDGEMENTS**

References:

- **ADDITIONAL REFERENCES**

Developing your review

Your protocol describes your review methods and it will guide you in developing your review. The editorial process for reviews is similar to that for a protocol.

When you have completed your review to your own satisfaction it should be submitted 'formally' to the Editorial Base. This means that it will again be entered into the Renal Group referee process. The same referees of the protocol also referee the review, with the addition of our Statistical Advisor. The comments from all referees will be provided to you by the Managing Editor. Following any necessary revisions and approval by the Editorial Team, the completed review is submitted to *The Cochrane Library* for publication. Once your review is published you are entitled to a free subscription to *The Cochrane Library* and you will receive a copy four times a year.

Updating your review

As the aim of The Cochrane Collaboration is to provide up to date information, you will be expected to update your review as required. This may involve inclusion of new trials relevant to your title or responding to comments and criticisms. The Trials Search Coordinator will regularly search the Trials Register for you and notify you when new trials are published.

In addition to updating your review, you may be contacted concerning issues relating to you review. You are expected to reply to these

comments and criticisms within an appropriate time frame, and they will appear in the next issue of *The Cochrane Library*.

How long should a review take?

A Cochrane review is never 'finished'. There are, however, steps along the way that we can roughly estimate.

Title to protocol	**approx. 3 months**
Protocol to review	**approx. 6-12 months**
Updates	**at least every 2 years (regular literature searches are made by the Trials Search Coodinator for you)**

Cochrane title format

The basic title format is

[intervention]* FOR *[health problem]
eg Antibiotics for acute bronchitis

Where two active interventions have been compared, the structure is:

[Intervention A]* VERSUS *[intervention B]* FOR *[health problem]
***eg* Immediate versus delayed treatment for cervical intraepithelial neoplasia**

Where the type of people studied or the location of the intervention is mentioned explicitly, the format is:

[Intervention]* FOR *[health problem]* IN *[participant group/location]
***eg* Inhaled nitric oxide for respiratory failure in preterm infants**

Sometimes it might be necessary to specify that the intervention is for preventing, treating, or preventing and treating the problem(s) concerned.

[Intervention]* FOR *[preventing and/or treating] [health problem]* IN *[participant group/location]
***eg* Pool fencing for preventing drowning in children**
Amodiaquine for treating malaria

For many prophylactic interventions there is often no specified 'health problem'

***[Intervention]* IN or FOR *[participant group/location]*.**
eg Restricted versus liberal water intake in preterm infants
Home-based social support for socially disadvantaged mothers

Cochrane Renal Group topic areas and scope

The Cochrane Renal Group's scope covers the following major areas of kidney disease.

- **Acute kidney injury**
- **Chronic kidney disease**
- **End-stage kidney disease**
- **Kidney transplantation**
- **Drugs and the kidney**
- **Renovascular hypertension**
- **Urinary tract infections**
- **Nephrolithiasis**

Published reviews, protocols and registered titles

To date we have 72 reviews and 80 protocols published in *The Cochrane Library* (www.thecochranelibrary.com) (Issue 3, 2009 release date July 2009). In addition we have 43 titles registered with our group. To see the most up-to-date list please go to http://www.cochrane.org/reviews/en/topics/89.html.

Published reviews

1) Aldosterone antagonists for preventing the progression of chronic kidney disease	Sankar Navaneethan
2) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease	Giovanni Strippoli
3) Antibiotic duration for uncomplicated symptomatic urinary tract infection in elderly women	Monika Lutters
4) Antibiotics for acute pyelonephritis in children	Elisabeth Hodson
5) Antibiotics for preventing recurrent urinary tract infection in non-pregnant women	Xavier Albert
6) Antifungal agents for preventing fungal infections in solid organ transplant recipients	E Geoffrey Playford
7) Antihypertensive agents for preventing diabetic kidney disease	Giovanni Strippoli
8) Antimicrobial agents for preventing infection in peritoneal dialysis patients	Giovanni Strippoli
9) Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients	Elisabeth Hodson
10) Biocompatible haemodialysis membranes for acute renal failure	Bertrand Jaber
11) Calcimimetics for secondary hyperparathroidism in chronic kidney disease patients	Giovanni Strippoli
12) Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients	Ilona Shilliday
13) Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients	Giovanni Strippoli
14) Cellulose, modified cellulose and synthetic membranes for the haemodialysis of patients with end-stage renal disease	Alison MacLeod
15) Chinese herbal medicine Huangqi type formulation for nephrotic syndrome	Yuan Wei
16) Continuous ambulatory peritoneal dialysis (CAPD) versus home or hospital haemodialysis for end-stage renal failure in adults	Luke Vale
17) Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease	Kannaiyan Rabindranath
18) Correction of chronic metabolic acidosis for chronic kidney disease patients	Paul Roderick
19) Corticosteroid therapy for nephrotic syndrome in children	Elisabeth Hodson

20) Cranberries for preventing urinary tract infections	**Ruth Jepson**
21) Cranberries for treating urinary tract infection	**Ruth Jepson**
22) Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease	**Conal Daly**
23) Duration of antibacterial treatment for uncomplicated urinary tract infection in women	**Gai Milo**
24) Effects of non-steroidal anti-inflammatory treatment on postoperative renal function in adults with normal renal function	**Anna Lee**
25) Emergency interventions for hyperkalaemia	**Catherine Clase**
26) Extracorporeal shockwave lithotripsy (ESWL) versus ureteroscopic retrieval for ureteric stones	**Ghalum Nabi**
27) Fish oil for kidney transplant recipients	**Karen Manley**
28) Fluids and diuretics for acute ureteric colic	**Andrew Worster**
29) Frequency of recombinant human erythropoeitin (rH EPO) for dialysis patients	**June Cody**
30) Growth hormone for children with chronic kidney disease	**Elisabeth Hodson**
31) Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease	**Kannaiyan Rabindranath**
32) Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease	**Giovanni Strippoli**
33) HMG Co-A reductase inhibitors (statins) for dialysis patients	**Sankar Navaneethan**
34) HMG CoA reductase inhibitors (statins) for kidney transplant recipients	**Sankar Navaneethan**
35) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis	**Sankar Navaneethan**
36) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients	**Elisabeth Hodson**
37) Immunosuppressive agents for treating IgA nephropathy	**Joshua Samuels**
38) Immunosuppressive treatment for focal segmental glomerulosclerosis in adults	**Norbert Braun**
39) Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome	**Arrigo Schieppata**
40) Interleukin 2 receptor antagonists for kidney transplant recipients	**Angela Webster**
41) Intermittent versus continuous renal replacement therapy for acute renal failure in adults	**Kannaiyan Rabindranath**
42) Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura	**Mini Michael**
43) Interventions for idiopathic steroid-resistant nephrotic syndrome in children	**Elisabeth Hodson**
44) Interventions for minimal change disease in adults with nephrotic syndrome	**Suetonia Palmer**
45) Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)	**Wattana Chartapisak**
46) Interventions for preventing bone disease in kidney transplant recipients	**Suetonia Palmer**
47) Interventions for preventing infection in nephrotic syndrome	**Hong Mei Wu**
48) Interventions for primary vesicoureteric reflux	**Elisabeth Hodson**
49) Interventions for renal vasculitis in adults	**Giles Walters**
50) Long term antibiotics for preventing recurrent urinary tract infection in children	**Gabrielle Williams**
51) Low protein diets for chronic kidney disease in non-diabetic adults	**Denis Fouque**
52) Methenamine hippurate for preventing urinary tract infections	**Bonne Lee**
53) Modes of administration of antibiotics for symptomatic	**Annette Pohl**

severe urinary tract infection	
54) Non-corticosteroid treatment for nephrotic syndrome in children	Elisabeth Hodson
55) Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic	Anna Holdgate
56) Oestrogens for preventing recurrent urinary tract infection in postmenopausal women	Carla Perrotta
57) Pharmacological interventions for preventing complications in idiopathic hypercalciuria	Joaquin Escribano
58) Physical measures for treating depression in dialysis patients	Kannaiyan Rabindranath
59) Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients	Angela Webster
60) Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients	Giovanni Strippoli
61) Protein restriction for children with chronic renal failure	Swasti Chaturvedi
62) Psychosocial interventions for depression in dialysis patients	Kannaiyan Rabindranath
63) Quinolones for uncomplicated acute cystitis in women	Vladimir Rafalskiy
64) Recombinant human erythropoïetin for chronic renal failure anaemia in pre-dialysis patients	June Cody
65) Routine intraoperative ureteric stenting for kidney transplant recipients	Colin Wilson
66) Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children	Elisabeth Hodson
67) Steroid avoidance or withdrawal for kidney transplant recipients	Julio Pascual
68) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients	Angela Webster
69) Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients	Angela Webster
70) Treatment for lupus nephritis	Steven Chadban
71) Treatment for peritoneal dialysis-associated peritonitis	Kate Wiggins
72) Water for preventing urinary calculi	Qiang Wei

Published protocols

1) Adjunctive therapies for HIV-associated nephropathy	Ismail Yahaya
2) Advanced glycation end product (AGE) inhibitors for preventing the progression of diabetic kidney disease	Andre Lemos
3) Altered dietary salt intake for preventing and treating diabetic kidney disease	Rebecca Suckling
4) Amphotericin B deoxycholate versus liposomal amphotericin B: effect on kidney function	Jason M Cota
5) Androgens for the anaemia of chronic kidney disease in adults	Taixiang Wu
6) Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non diabetic chronic kidney disease	Corri Black
7) Antibiotics for asymptomatic urinary tract infection in the elderly	Fatima G Capella
8) Antibiotics for preventing urinary tract infections in kidney transplant recipients	Abdulmalik Alkatheri
9) Antibiotics for treating uncomplicated urinary tract infection in children	Anita Fitzgerald
10) Antibody immunosuppression for pancreas and kidney/pancreas transplant recipients	Kathy Kable
11) Antihypertensive agents for dialysis patients	Cesar Loza Munarriz
12) Antihypertensive agents for preventing the progression of diabetic kidney disease (Non-ACEi, non-ARB review)	Giovanni Strippoli

13) Antihypertensive therapy for kidney transplant recipients	**Nicholas Cross**
14) Antimicrobial agents for treating uncomplicated urinary tract infection in women	**Anca T Zalmanovici**
15) Atrial natriuretic peptide for preventing and treating acute kidney injury	**Sagar Nigwekar**
16) Bicarbonate versus lactate solutions for acute haemodialysis	**Kehu Yang**
17) Bicarbonate versus lactate solutions for acute peritoneal dialysis	**Kehu Yang**
18) Biocompatible dialysis fluids for peritoneal dialysis	**Kate Wiggins**
19) Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients	**Krishna Karpe**
20) Calcium channel blockers for ureteral stones	**Andrew Worster**
21) Cephalosporins for treating acute uncomplicated pyelonephritis in adults	**Mazen Ferwana**
22) Chinese medicinal herbs for diabetic kidney disease	**Jianping Liu**
23) Chinese medicinal herbs for urinary calculi	**Liang Du**
24) Continuous renal replacement therapies for acute renal failure in critically ill patients	**Alicia Fayad**
25) Contrast agents for preventing contrast-induced nephropathy	**Wiktoria Lesniak**
26) Dietary interventions for preventing complications in idiopathic hypercalciuria	**Joaquin Escribano**
27) Donor organ preservation techniques for kidney transplantation	**Colin Wilson**
28) Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease	**Neil Smart**
29) Education programmes for people with diabetic kidney disease	**Hongmei Wu**
30) Endoscopic treatment with or without stenting for the management of ureteric calculi	**Kesavapillai Subramonian**
31) Exercise training for adults with chronic kidney disease	**Susanne Heiwe**
32) Extracorporeal shock wave lithotripsy (ESWL) for kidney stones	**Attasit Srisubat**
33) Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity	**Florian Buchkremer**
34) Glycosaminoglycan for preventing and treating diabetic kidney disease	**Li Jun**
35) Growth factors for chronic kidney disease in adults	**Ghazwan Altabbaa**
36) High-flux versus low-flux haemodialysis membranes for end-stage kidney disease	**Kannaiyan Rabindranath**
37) Human albumin for intradialytic hypotension in haemodialysis patients	**Patricia Fortin**
38) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function	**Allison Dart**
39) Insulin-sensitising therapies for preventing the progression of diabetic kidney disease	**Huai-Sheng Chen**
40) Intensive versus standard haemodialysis water treatment for preventing low grade mineral intoxication in chronic haemodialysed patients	**Marcelo Chaves**
41) Interventions for covert bacteriuria in children	**Anita Fitzgerald**
42) Interventions for dialysis patients with hepatitis C virus (HCV) infection	**Ravindra Prabhu**
43) Interventions for dialysis-associated restless legs syndrome	**Keith Wong**
44) Interventions for erythropoietin-resistant anaemia in dialysis patients	**Sha Liang**
45) Interventions for lowering plasma homocysteine levels in dialysis patients	**Sagar Nigwekar**
46) Interventions for lowering plasma homocysteine levels in kidney transplant recipients	**Meg Jardine**
47) Interventions for preventing clotting of extracorporeal	**Suzi Robertson-Malt**

circuits during continuous renal replacement therapy	
48) Interventions for preventing haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura	**Elizabeth Elliott**
49) Interventions for preventing infectious complications in haemodialysis patients with central venous lines	**Margaret McCann**
50) Interventions for preventing thrombosis in adults and children with nephrotic syndrome	**Satyarth Kulshrestha**
51) Interventions for treating sexual dysfunction in patients with chronic kidney disease	**Mariacristina Vecchio**
52) Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units	**Jessica Bravo**
53) Laparoscopic versus open nephrectomy for live kidney donors	**Colin Wilson**
54) Lipid-lowering agents for nephrotic syndrome	**C Haiyan**
55) Long-term nutritional interventions for adult kidney transplant recipients	**Karen Fry**
56) Low molecular weight heparin for diabetic kidney disease	**Taixiang Wu**
57) Methods for collecting urine samples in adults and children with suspected urinary tract infection	**Joseph Thomas**
58) Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients	**Angela Webster**
59) Non-immunosuppressive agents for Ig A nephropathy	**Sharon Reid**
60) Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic	**Kourish Afshar**
61) Nutritional support for acute kidney injury	**Fenglei Xu**
62) Oral adsorbents for preventing or delaying the progression of chronic kidney disease	**Hong Mei Wu**
63) Parenteral versus oral iron therapy for adults and children with chronic kidney disease	**Elisabeth Hodson**
64) Pentoxifylline for diabetic kidney disease	**Hong Mei Wu**
65) Pharmacological interventions for preventing contrast-induced nephropathy	**Wiktoria Lesniak**
66) Pharmacological interventions for preventing recurrent urinary stones in adults and children	**Joseph Thomas**
67) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients	**Sankar Navaneethan**
68) Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients	**Angela Webster**
69) Preoperative vascular access evaluation for haemodialysis patients	**Charmaine Lok**
70) Prostaglandin E1 for preventing the progression of diabetic kidney disease	**Wang Han**
71) Recombinant human insulin-like growth factor I for acute kidney injury	**Kehu Yang**
72) Renal replacement therapy for preventing contrast-induced nephropathy	**Wiktoria Lesniak**
73) Steroid avoidance or withdrawal for pancreas and kidney transplant recipients	**Julio Pascual**
74) Tacrolimus versus cyclosporin for simultaneous kidney-pancreas transplant recipients	**Shu shi Huang**
75) Teicoplanin versus vancomycin for proven or suspected infection	**Alexandre Cavalcanti**
76) Therapeutic interventions for idiopathic membranoproliferative glomerulonephritis	**Ping Fu**
77) Thyroxine for acute kidney injury	**Sagar Nigwekar**
78) Tidal peritoneal dialysis for acute renal failure	**Lei Jiang**
79) Ultrasound use for the placement of haemodialysis catheters	**Emma Vaux**
80) Vitamin D compounds for people with chronic kidney disease requiring dialysis	**Suetonia Palmer**

Registered titles

1) Alpha-blockers as medical-expulsive therapy for ureteral stones	Yefang Zhu
2) Amino acid containing peritoneal solutions for peritoneal dialysis patients	Per Ivarsen
3) Angiotensin converting enyzme inhibitors and angiotensin II receptor blockers for preserving residual kidney function in peritoneal dialysis patients	Ling Zhang
4) Antibiotic lock therapy for preventing dialysis catheter related infections in hemodialysis patients	Sankar Navaneethan
5) Antioxidants for chronic kidney disease	Vlado Perkovic
6) Antiplatelet agents for people with chronic kidney disease not requiring dialysis	Giovanni Strippoli
7) Calcium dialysate concentration for peritoneal dialysis	Ma Bin
8) Continuous renal replacement therapy (CRRT) for rhabdomyolysis	Ping Fu
9) Cordyceps sinersis (a Chinese medicinal herb) for treating chronic kidney disease	Hongwei Zhang
10) Dialysate temperature control for haemodialysis	Jinhui Tian
11) Dialyser reuse for chronic haemodialysis patients	Satyarth Kulshrestha
12) Diuretics for nephrotic syndrome	Pavel Geier
13) Dopamine for acute kidney injury	Kehu Yang
14) FTY720 as maintenance immunosuppression for kidney transplant recipients	Jiying Tan
15) Haemodialysis duration and frequency for end-stage kidney disease	Vlado Perkovic
16) HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass	Patrick Murray
17) Human albumin infusion for nephrotic syndrome	Zainal Darus
18) Interventions for bone disease in children with chronic kidney disease	Denis Geary
19) Interventions for lowering plasma homocysteine levels in pre-dialysis patients	Kingsley Urakpo
20) Interventions for treating hypertension in adults and children with acute post infectious glomerulonephritis	Thara Basavaiah
21) Loop diuretics for acute kidney injury in adults and children	Watanyu Parapiboon
22) Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) for haemodialysis anticoagulation	Xi-Sheng Xie
23) Maintenance calcineurin inhibitor levels for kidney transplant recipients	Juqian Zhang
24) Nutritional supplements for adults with end-stage kidney disease on renal replacement therapy	Kanwardeep Sachdeva
25) Percussion, diuresis and inversion therapy for the passage of lower pole kidney stones after shock wave lithotripsy	Liang Ren Liu
26) Percutaneous angioplasty or stenting for stenosed but functioning haemodialysis access fistulae and grafts	Raman Uberoi
27) Probiotics for preventing urinary tract infections	Aaron Tejani
28) Radix astragali (a Chinese medicinal herb) for chronic kidney disease	Hongwei Zhang
29) Rhubarb (a Chinese medicinal herb) for chronic kidney disease	Han Wang
30) Routine biopsies for kidney transplant recipients	Kannaiyan Rabindranath
31) Short versus standard duration haemodialysis for end-stage renal disease	Kannaiyan Rabindranath
32) Single dose antibiotics for treating uncomplicated urinary tract infection in nonpregnant, premenopausal women	ZhiPing Wang
33) Single dose antibiotics for treating urinary tract infection	Siavash Jafari

in children	
34) Single versus simultaneous-double pediatric donor organs for adult kidney transplant recipients	Qing Yuan
35) Sodium bicarbonate supplements for acute kidney injury	Kushma Nand
36) Sodium ferulate for preventing the progression of diabetic kidney disease	Xiang Yan
37) Standard versus high Kt/V or creatinine clearance for chronic haemodialysis patients	Kannaiyan Rabindranath
38) Support interventions for caregivers of patients with chronic kidney disease	Allison Tong
39) Topical corticosteroids for treating phimosis in boys	Gladys Moreno
40) Treatment of BK virus nephropathy in renal transplant recipients	Sree Krishna Venuthurupalli
41) Tubeless versus standard percutaneous nephrolithotomy for treating kidney stones	Hong Li
42) Vascular access surveillance for patients on haemodialysis	Louise Moist
43) Vitamin D compounds for people with chronic kidney disease not requiring dialysis	Suetonia Palmer

Contact Details

Cochrane Renal Group
Centre for Kidney Research
Locked Bag 4001
Westmead, NSW 2145
Australia
Tel: +61 (0)2 9845 1478
Fax: +61 (0)2 9845 1491
Email: crg@chw.edu.au
Web: www.cochrane-renal.org

Upcoming meetings and workshops

For an up-to-date list please contact our office or go to

http://www.cochrane.org/news/workshops.htm

The Cochrane Renal Group

FAX-BACK FORM

I am interested in undertaking a Cochrane systematic review on the following topic

Provisional title ***(Intervention for health condition in population)***

.....

.....

.....

(Please give a brief description of)

Participants: .....

.....

.....

Interventions: .....

.....

.....

Outcomes: .....

.....

.....

Contact details of primary author:

Name: .....

Email: .....

Is there any potential conflict of interest? (e.g. Involved in clinical trials in the field or funding from the pharmaceutical industry etc. if none, please write 'none known')

.....

.....

Please send me a copy of the Cochrane Renal Group's title registration form.

Please fax to +61 (0)2 9845 1491